Communiqués Mosaic ImmunoEngineering, Inc.

Actions

CPMV

US61945M1018

Marché Fermé - OTC Markets Autres places de cotation 18:27:27 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,5799 ^USD	-4,93 %		+5,44 %	-3,35 %

14/05	Mosaic ImmunoEngineering, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
19/04	Mosaic Immunoengineering, Inc. annonce le décès de Gloria Felcyn, administratrice indépendante et membre du comité d'audit, du comité de rémunération et du comité de gouvernance d'entreprise et de nomination	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	29/04	AQ
Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K	28/03	PU
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)	03/05/23	AQ
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	02/03/23	AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	01/11/22	AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	04/08/22	AQ
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	12/07/22	AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10/05/22	AQ
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	05/05/22	AQ
MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)	22/02/22	AQ
Mosaic ImmunoEngineering : Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma	02/02/22	PU
MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	26/01/22	AQ
MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	02/11/21	AQ
Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation	01/11/21	PU
Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference	20/10/21	PU
Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering’s Immuno-Oncology and Modular Vaccine Platform Candidates	12/10/21	PU
MOSAIC IMMUNOENGINEERING : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	03/08/21	AQ
Mosaic ImmunoEngineering : Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors (Form 8-K)	15/06/21	PU
MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	15/06/21	AQ
Mosaic ImmunoEngineering : Form of Convertible Note Purchase Agreement (Form 8-K)	12/05/21	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Mosaic ImmunoEngineering, Inc.

Actions

CPMV

US61945M1018

Communiqués

Filtres